HMR launches Refludan in US

01 July 1998 20:37  [Source: ICIS news]

HOUSTON (CNI)--Hoechst Marion Roussel (HMR) announced Wednesday the US launch of Refludan, the first product approved in the US to treat patients with thromboembolic complications associated with heparin-induced thrombocytopenia (HIT).

HIT is a rare, allergy-like adverse reaction to heparin, a standard anticoagulant (anti-blood-clotting) therapy commonly used in a variety of settings ranging from orthopedic surgery to acute coronary care.

"Prior to the release of Refludan, the only way to manage HIT was to discontinue heparin. Refludan fills a gaping hole in the management of this potentially life-threatening condition by providing an effective anticoagulant treatment that facilitates rapid recovery of platelet counts with reduced risk of blood clots," said Jerry Belle, president of HMR North America.

The drug is available in 50-mg vials for intravenous administration.

HMR is headquartered in Kansas City, Missouri and is the pharmaceutical company of Hoechst AG of Frankfurt, Germany.

By: Mary Ann Tawasha
+1 713 525 2653

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly